Home
About
Overview
Sharing Data
ORCID
Help
History (1)
IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease.
IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease. J Crohns Colitis. 2020 Jan 01; 14(1):23-32.
View in:
PubMed
subject areas
Crohn Disease
Double-Blind Method
Drug Administration Schedule
Humans
Injections, Subcutaneous
Maintenance Chemotherapy
Treatment Outcome
Ustekinumab
authors with profiles
Stephen B. Hanauer